Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Capital Expenditures (2016 - 2025)

Anaptysbio filings provide 10 years of Capital Expenditures readings, the most recent being $1000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 99.62% year-over-year to $1000.0, compared with a TTM value of $87000.0 through Dec 2025, down 75.7%, and an annual FY2025 reading of $87000.0, down 75.7% over the prior year.
  • Capital Expenditures hit $1000.0 in Q4 2025 for Anaptysbio, down from $12000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $1.1 million in Q2 2021, with the low at -$271000.0 in Q4 2023.
  • Median Capital Expenditures over the past 5 years was $30000.0 (2024), compared with a mean of $98650.0.
  • The sharpest move saw Capital Expenditures soared 3540.0% in 2021, then crashed 834.48% in 2023.
  • Year by year, Capital Expenditures stood at $14000.0 in 2021, then plummeted by 307.14% to -$29000.0 in 2022, then tumbled by 834.48% to -$271000.0 in 2023, then soared by 197.05% to $263000.0 in 2024, then plummeted by 99.62% to $1000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1000.0, $12000.0, and $63000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.